Skip to content

DEVAPHAR

Active
Private limited company·Detailhandel in farmaceutische producten· 25 yrs active
Louizalaan 200 ·1050 Brussel, Belgium
KBO/BCE: BE 0474.481.042
Watch Print / PDF
Age25 yrs

Summary

Conclusion

the dossier summarised in one paragraph

The file of DEVAPHAR contains 1 judicial reorganisation, as published in the Belgian State Gazette. The computed 12-month bankruptcy probability is ≥ 25% (high). The 2024 annual accounts show equity of €654k and a net result of €49k. Equity is growing by ~27.3% per year across the filed fiscal years. Its solvency ranks better than 68% of 6696 sector peers (fiscal year 2024).

Based on the State Gazette, CBE and 7 annual accounts.

Bankruptcy probability (12 mo)

Checked model v1 · free for everyone
≥ 25% High
0%0,5%1,5%4%10%≥25%
Judicial reorganisation on record +Recent warning signals +Higher-failure-rate region +

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Insolvency timeline

1 events
02-06-2026
Judicial reorganisation Opening
Date: 26-05-2026 · Tribunal de l’entreprise francophone de Bruxelles · collectif_pme · Publications in State Gazette ↗

Trust signals

1 signal
In judicial reorganisation
Ongoing procedure under court protection (Book XX WER). The company is restructuring.

Administrative Flags

0 events
No administrative flags

Financials

TurnoverNot published (abbreviated filing)
EBIT marginNot published (abbreviated filing)
Net result€49k-27.7%
Working capital€464k+48.3%

Annual accounts & ratios

Source: NBB · 2024
Annual accounts filed on 14-11-2025 with the NBB · fiscal year 2024 · micro
€0€100k€200kOperating result 2020: €126k€126kNet result 2020: €85k€85kOperating result 2021: €149k€149kNet result 2021: €91k€91kOperating result 2022: €236k€236kNet result 2022: €159k€159kOperating result 2023: €139k€139kNet result 2023: €68k€68kOperating result 2024: €80k€80kNet result 2024: €49k€49k20202021202220232024
Operating resultNet result
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
growing Equity: growth of ~27.3%/year over 7 fiscal years, indicative, assuming unchanged policy.
€0€500k€1.00M€1.50M2025: €981k (€928k - €1.03M)2026: €1.25M (€1.20M - €1.30M)2027: €1.59M (€1.54M - €1.64M)2018: €181k2019: €202k2020: €287k2021: €378k2022: €537k2023: €605k2024: €654k2018201920202021202220232024202520262027
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?

The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.

The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.

A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).

Sector comparison
Fiscal year 2024 · NACE 47, Retail trade · compared within the same schema type (micro schema)
Metric This company Sector median Position in the sector
Solvency 40.2% 20.4%
better than 68% of 6696 sector peers
Net result €49k €4k
better than 89% of 6676 sector peers
Equity €654k €16k
better than 95% of 6710 sector peers
Gross operating margin €262k €24k
better than 95% of 6655 sector peers
Staff costs €123k €33k
higher than 88% of 3033 sector peers
Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.
Sector position over time
Percentile per fiscal year versus peers that filed figures, computed year by year (a year without enough peers is absent).
Solvency P68
2020: P66 · n=13522021: P76 · n=25282022: P74 · n=42792023: P64 · n=57062024: P68 · n=66962020 2024
Stable position over 2020-2024 · n=1352-6696
Net result P89
2020: P95 · n=13482021: P95 · n=25212022: P95 · n=42672023: P94 · n=56862024: P89 · n=66762020 2024
Stable position over 2020-2024 · n=1348-6676
Equity P95
2020: P94 · n=13542021: P95 · n=25312022: P95 · n=42872023: P95 · n=57132024: P95 · n=67102020 2024
Stable position over 2020-2024 · n=1354-6710
Gross operating margin P95
2020: P93 · n=13432021: P95 · n=25082022: P95 · n=42572023: P95 · n=56602024: P95 · n=66552020 2024
Stable position over 2020-2024 · n=1343-6655
Describes the position versus peers, not a forecast.
EBITDA
€107k
-33.9% +3% vs sector
Net profit
€49k
-27.7% -16% vs sector
Cash flow
€76k
-16.0% -11% vs sector
Total assets
€1.63M
-8.0% +167% vs sector
Equity
€654k
+8.1% far above sector median
Working capital
€464k
+48.3% far above sector median
Employees (FTE)
2
- -44% vs sector
Staff costs
€123k
+1.0% -51% vs sector
Income taxes
€51k
-37.6% far above sector median
Debt
€972k
-16.4% +89% vs sector
Debt ≤ 1y
€972k
-16.4% +142% vs sector
Debt > 1y
€0
-100.0% -100% vs sector
Current ratio
1.48
+16.4% +52% vs sector
Quick ratio
1.29
+17.1% +256% vs sector
Solvency
40.2%
+17.5% +181% vs sector
Debt / equity
1.49
-22.6% -75% vs sector
ROE
7.5%
-33.1% -88% vs sector
ROA
3.0%
-21.4% -68% vs sector
Interest coverage
3.45
-49.3% -41% vs sector
Figures by fiscal year
Fiscal year2024
Revenue-
EBITDA€107k
Net profit€49k
Cash flow€76k
Staff costs€123k
Income taxes-
Dividends-
Total assets€1.63M
Equity€654k
Debt€972k
of which ≤ 1y€972k
of which > 1y-
Working capital€464k
Employees (FTE)-
Ratios (computed)
2024
Current ratio1.48
Quick ratio1.29
Working capital ratio28.5%
Solvency40.2%
Debt / equity1.49
Long-term debt ratio-
Interest coverage3.45
Gross margin-
Net margin-
ROA3.0%
ROE7.5%
EBITDA margin-
Days sales outstanding-
Days payable outstanding-
Inventory turnover-
Days inventory (DSI)-
Balance-sheet composition 2024
Full annual accounts
Filed balance sheet and income statement, exactly as deposited with the NBB.
Line item Code2024
Balance sheet, Assets
TOTAL ASSETS 20/58€1.63M
Fixed assets 21/28€190k
Intangible fixed assets 21€3k
Tangible fixed assets 22/27€186k
Financial fixed assets 28€1k
Current assets 29/58€1.44M
Stocks & contracts in progress 3€183k
Amounts receivable within one year 40/41€1.03M
Investments 50/53€14k
Cash & bank 54/58€6k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES 10/49€1.63M
Equity 10/15€654k
Contributions / capital 10/11€6k
Reserves 13€372k
Accumulated profits (losses) 14€276k
Amounts payable 17/49€972k
Amounts payable within one year 42/48€972k
Trade debts payable within one year 44€739k
Income statement
Gross operating margin 9900€262k
Operating result 9901€80k
Financial income 75€12
Financial charges 65€31k
Result before taxes 9903€49k
Net result for the period 9904€49k
Result to be appropriated 9905€49k
You're seeing the latest fiscal year only. Unlock 4 prior years (figures + ratios) with a paid plan. See plans →
Ratios computed by Checked.

Health barometer

FY 2024 · computed
54 / 100 Fair
050100

Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.

See plans →
Computed by Checked from NBB filings and Belgian State Gazette signals. Indicative, not credit advice.

Structure & network

Locations & real estate

Establishment units

2 locations
Neerstallesteenweg 485, 1180 Ukkel
Bemiddelingsactiviteiten in verband met goederenvervoer
since 20012.100.261.915
PHARMACIE APOTEEK
Sterstraat 96, 1620 DrogenbosBemiddelingsactiviteiten in verband met goederenvervoer
since 20012.100.262.014
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Parcels3
Ground area1,737 m²
Buildings3
Building footprint1,348 m²
Volume (LiDAR)25,581 m³
Tallest building30.6 m · ±7 fl.

Real-estate footprint

Source: CBE × cadastre · address linking

Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.

Flanders 1 (33.3%) Brussels 2 (66.7%)
Parcel (capakey) Region Area Buildings Height / fl.
21807G0121/00B008 Brussels 1,451 m² 1 · 1,103 m² 30.6 m · 7 fl.
22001B0108/00W005 Flanders 169 m² 1 · 131 m² 11.8 m · 3 fl.
21616G0097/00S006 Brussels 117 m² 1 · 114 m² 12.8 m · 3 fl.
Methodology
via registered seat: 1 · via establishment units: 2
3 of 3 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Publications

Lifecycle & Insolvency Signals

1 event from the State Gazette
02-06-2026
Judicial reorganisation Opening
Date: 26-05-2026 · Tribunal de l’entreprise francophone de Bruxelles · collectif_pme · Publications in State Gazette ↗

Time machine: BS events + macro context

2021-2026
COVID lockdownEnergiecrisisECB hikes2021202220232024202520262026-06-02 · Judicial reorganisation · Opening
Macro context
2020-Q2/Q3 COVID lockdown
2022 energy crisis
2023-2024 ECB rate hikes
Legend
Bankruptcy
Interim / reorg
KBO event

Belgisch Staatsblad · acts

2 acts
Address history · 1
18-11-2024
Registered-office move
All acts · 2 updated 1 year ago
2024
18-11-2024 Registered office moved from Anderlecht to Bruxelles Registered-office change·Samuel WYNANT
  • Avenue Victor Olivier 6 bte 21 : 1070 Anderlecht → 1050 Bruxelles, avenue Louise 200 boîte 8
Notary: Samuel WYNANT · BruxellesFirm: Van Halteren Notaires
18-11-2024 Van Halteren Notarissen appointed as daily management Director changes·Samuel WYNANT
  • Van Halteren Notarissen, Dagelijks bestuur
Notary: Samuel WYNANT · BrusselFirm: Van Halteren Notarissen

Analysis

Snowflake analysis

financial profile on 5 axes
Health54Profitability38Solvency72Growth78Stability60
60 / 100

Strong profile, led by growth.

Health 54
Profitability 38
Solvency 72
Growth 78
Stability 60

Ask AI about this company

Checked AI

Soon: ask questions about this dossier, risks, curator, sector comparison, answered from the official data on this page.

TryWhat are the main risks?Any recent red flags?Compare to sector peers
Coming soon

AI due-diligence brief

Checked AI

Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.

Coming soon
AI-generated from Checked data; indicative, not legal or investment advice.

Credit advice

verdict per customer and amount

Should this customer buy amount X on invoice? Enter the amount and payment terms, you get an instant GREEN/AMBER/RED verdict, with a suggested ceiling and concrete conditions.

Based on official sources (NBB, CBE, State Gazette). Indicative, not credit advice.

Similar

Similar companies

Same sector, ranked by comparable size

Company registry

Company registry (CBE)

Crossroads Bank
Activities
Apotheken47730Detailhandel in farmaceutische producten47730Apothekers52310
Primary activity highlighted.
Names & trade names
Legal nameFR DEVAPHAR
Legal nameNL DEVAPHAR
Registered office
Louizalaan 200 bus 8
1050 Brussel, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.